scholarly journals Analysis of clinical symptoms, radiological changes, and pulmonary function data 4 months after COVID‐19

2021 ◽  
Author(s):  
Gonzalo Labarca ◽  
Mario Henríquez‐Beltrán ◽  
Jaime Lastra ◽  
Daniel Enos ◽  
Faryd Llerena ◽  
...  
Keyword(s):  
Pulmonary Function ◽  
Clinical Symptoms ◽  
Function Data ◽  
Radiological Changes

Complex Pulmonary Function Data

CHEST Journal ◽  
1983 ◽  
Vol 84 (2) ◽  
pp. 121 ◽  
Author(s):  
Richard J. Martin
Keyword(s):  
Pulmonary Function ◽  
Function Data

Using Pulmonary Function Data to Assess Outcomes in the Endoscopic Management of Subglottic Stenosis

2014 ◽  
Vol 124 (2) ◽  
pp. 137-142 ◽  
Author(s):  
Shannon M. Kraft ◽  
Kevin Sykes ◽  
Andrew Palmer ◽  
Joshua Schindler
Keyword(s):  
Pulmonary Function ◽  
Subglottic Stenosis ◽  
Endoscopic Management ◽  
Function Data

scholarly journals Diffusion Capacity Abnormalities for Carbon Monoxide in Patients with COVID-19 At Three-Month Follow-up

2021 ◽  
pp. 2003677
Author(s):  
Wei Qin ◽  
Shi Chen ◽  
Yunxia Zhang ◽  
Fen Dong ◽  
Zhu Zhang ◽  
...  
Keyword(s):  
Carbon Monoxide ◽  
Pulmonary Function ◽  
Clinical Symptoms ◽  
Pulmonary Function Tests ◽  
Chest Ct ◽  
Test Results ◽  
Diffusion Capacity ◽  
Impaired Lung Function ◽  
Multivariable Regression

ObjectiveTo evaluate pulmonary function and clinical symptoms in coronavirus disease 2019 (COVID-19) survivors within 3 months after hospital discharge, and to identify risk factors associated with impaired lung function.Methods and materialCOVID-19 patients were prospectively followed up with pulmonary function tests and clinical characteristics for 3 months following discharge from a hospital in Wuhan, China between January and February 2020.Results647 patients were included. 87 (13%) patients presented with weakness, 63 (10%) with palpitation and 56 (9%) with dyspnea. Prevalences of the three symptoms were markedly higher in severe patients than non-severe patients (19% versus 10% for weakness, p=0.003; 14% versus 7% for palpitation, p=0.007; 12% versus 7% for dyspnea, p=0.014). Results of multivariable regression showed an increased odd in the ongoing symptoms among severe patients (OR: 1.7, 95%CI: 1.1–2.6, p=0.026) or patients with longer hospital stay (OR: 1.03, 95%CI: 1.00–1.05, p=0.041). Pulmonary function test results were available for 81 patients, including 41 non-severe and 40 severe patients. In this subgroup, 44 (54%) patients manifested abnormal diffusion capacity for carbon monoxide (DLCO) (68% severe versus 42% non-severe patients, p=0.019). Chest CT total severity score (TSS)>10.5 (OR: 10.4; 95%CI: 2.5–44.1; p=0.001) on admission and ARDS (OR: 4.6; 95%CI: 1.4–15.5; p=0.014) were significantly associated with impaired DLCO. Pulmonary interstitial damage may be associated with abnormal DLCO.ConclusionPulmonary function, particularly DLCO, declined in COVID-19 survivors. This decrease was associated with TSS of chest CT >10.5 and ARDS occurrence. Pulmonary interstitial damage might contribute to the imparied DLCO.

Correction: Pulmonary Function Data

1972 ◽  
Vol 76 (6) ◽  
pp. 1047
Author(s):  
ARNOLD ABERMAN
Keyword(s):  
Pulmonary Function ◽  
Function Data
Sign in / Sign up

Export Citation Format

Share Document